New Research Supports Long-Term, Low-Dose Antiviral Use for Shingles-Induced Eye Disease

Introduction of the Study

Shingles, caused by the reactivation of the varicella-zoster virus (the same virus responsible for chickenpox), affects millions of people worldwide, especially older adults. The condition often manifests as a painful rash but can lead to serious health complications. When shingles affects the eye, termed herpes zoster ophthalmicus (HZO), patients are at risk for severe issues like keratitis, iritis, and in rare cases, vision loss. 

Fortunately, recent findings from the Zoster Eye Disease Study (ZEDS) suggest that long-term, low-dose antiviral treatment can reduce the risk of eye disease and pain recurrence for those affected by shingles-related complications, opening up new avenues for patient care and quality of life improvement.

Understanding Shingles and Its Complications

Shingles can bring about more than just a painful rash; its complications can lead to lasting health challenges. Knowing these potential effects is essential to managing and preventing long-term impacts.

What Is Shingles?

Shingles is a painful reactivation of the varicella-zoster virus, which lies dormant in the body after an individual has recovered from chickenpox. This condition typically presents with a distinctive rash and blisters, most commonly on one side of the torso. While anyone with a history of chickenpox can develop shingles, it disproportionately affects older adults, especially those with weakened immune systems. 

Beyond the rash, shingles often brings burning or tingling sensations and sensitivity in the affected area, which may lead to long-term complications if not treated promptly. Vaccines like Shingrix have been developed to minimize the risk of shingles, especially in older adults who are more susceptible to severe symptoms.

Herpes Zoster Ophthalmicus (HZO)

In about 8% of shingles cases in the U.S., the virus reactivates in the ophthalmic nerve, affecting the eye. This condition, known as herpes zoster ophthalmicus (HZO), leads to inflammation in and around the eye and can result in keratitis (corneal inflammation) and iritis (inflammation of the iris). 

Such inflammation, if untreated, may lead to chronic conditions, permanent scarring, and vision impairment. HZO symptoms include eye redness, pain, light sensitivity, and swelling, sometimes extending to the eyelid. The risk of severe complications makes it essential for individuals with HZO to seek medical attention promptly to prevent long-term damage to their vision and eye health.

Postherpetic Neuralgia (PHN)

Postherpetic neuralgia (PHN), a common complication of shingles, occurs when nerve pain persists long after the rash and blisters have healed. This neuropathic pain can be specifically challenging to manage and is often chronic, with symptoms ranging from burning sensations to extreme sensitivity, requiring specialized pain management interventions. PHN pain can be debilitating, affecting day-to-day activities. 

Standard treatments often include nerve pain medications, such as gabapentin or pregabalin, though their effectiveness can vary, and side effects are a concern. Due to the persistent nature of PHN, prevention through shingles vaccination and early treatment of symptoms remain highly important.

Can People with Shingles-Induced Eye Disease Wear Contacts?

No. People with shingles-induced eye disease are typically advised against wearing contact lenses, especially during the active phases of the infection. Shingles in the eye can lead to severe inflammation, including conditions like keratitis (corneal inflammation), uveitis (inflammation within the eye), and other complications that may result in scarring, reduced vision, or, in severe cases, blindness. 

Contact lenses can exacerbate these symptoms by irritating already inflamed tissue, increasing the risk of infection, and complicating the healing process. Doctors generally recommend avoiding contacts until all signs of inflammation, pain, and irritation have subsided and an eye specialist approves their use.

Even after the acute stage, some patients may experience persistent dryness or discomfort due to nerve damage caused by shingles, which can make contact lens wear uncomfortable or unsafe. Medical experts advise ongoing consultation with an ophthalmologist before resuming contact lenses, as they may recommend specialized lens types or added precautions if dryness or scarring has occurred. 

Furthermore, managing shingles in the eye promptly with antiviral treatments and, if needed, corticosteroid eye drops can reduce the risk of lasting damage, allowing patients the best chance of safely returning to contact lens use in the future. Early intervention is important for preventing complications and maintaining long-term eye health.

Traditional Treatments for Shingles and Their Limitations

Shingles is commonly treated with a short-term antiviral regimen and pain management medications, aimed at alleviating the acute symptoms and reducing initial discomfort. However, these treatments often fall short of preventing long-term complications, such as eye disease or chronic pain, leaving many patients with lasting issues. As shingles research advances, understanding the limitations of traditional treatments sheds light on the importance of alternative approaches for better patient outcomes.

Current Antiviral Treatments

The current standard treatment for shingles involves a short 7- to 10-day course of antiviral medication, typically prescribed within 72 hours of rash onset. This timely intervention helps mitigate acute symptoms and shortens the initial episode, allowing many patients to recover quickly. 

Despite this, traditional antiviral courses do not fully prevent complications such as herpes zoster ophthalmicus (HZO) or postherpetic neuralgia (PHN), leaving patients susceptible to recurrence or long-term discomfort. For those affected by shingles-related eye disease, the limitations of short-term antiviral therapy highlight the need for sustained treatment options.

Challenges with Pain Management

For those who develop PHN, pain management is a vital part of post-shingles care. Neuropathic pain medications, including pregabalin and gabapentin, are commonly prescribed to alleviate symptoms of burning, tingling, and extreme sensitivity. While these medications can offer relief, they are often accompanied by side effects like dizziness, drowsiness, and impaired balance, which can significantly affect older adults’ quality of life. 

The limited efficacy of neuropathic pain medications also means that many patients require alternative or additional interventions to achieve substantial relief, making long-term pain management a complex challenge for patients and healthcare providers alike.

The Zoster Eye Disease Study (ZEDS)

The Zoster Eye Disease Study (ZEDS) is a large-scale clinical trial that investigates whether long-term, low-dose antiviral therapy with valacyclovir can reduce the recurrence of eye complications and pain associated with herpes zoster ophthalmicus (HZO), a form of shingles affecting the eye. 

Conducted across multiple centers in the U.S., Canada, and New Zealand, ZEDS aims to prevent or lessen chronic issues such as keratitis and postherpetic neuralgia, which are often severe in older adults with HZO​. Funded by the National Eye Institute, the study’s results could pave the way for more effective, long-term treatment strategies for HZO patients at risk of significant eye damage.

Overview of the Study

The Zoster Eye Disease Study (ZEDS) represents a groundbreaking effort to understand the long-term effects of antiviral treatment on herpes zoster ophthalmicus (HZO) complications. Spanning eight years, this clinical trial engaged 527 participants from 95 medical centers across the U.S., Canada, and New Zealand. 

The study aimed to determine if prolonged low-dose valacyclovir (Valtrex) could effectively prevent or reduce new and worsening cases of eye disease among those affected by HZO. Preventing eye disease progression and reducing reliance on pain management, ZEDS has set a significant precedent for future antiviral treatment approaches.

Study Design

Conducted as a double-masked study, ZEDS ensured that neither participants nor the researchers knew who was receiving the antiviral treatment versus a placebo, maintaining the study’s integrity and objectivity. This design involved administering either low-dose valacyclovir or a placebo to participants over a prolonged period, allowing researchers to track the effects on eye disease severity and the need for neuropathic pain medication. 

This rigorous approach helped the study isolate the impact of valacyclovir on both the frequency and intensity of HZO-related eye disease and chronic pain symptoms, providing robust data on its potential as a long-term treatment.

Funding and Leadership

Led by Dr. Elisabeth Cohen, the ZEDS initiative was made possible through funding from the National Eye Institute (NEI) and NYU Langone Health. Dr. Cohen’s journey was a personal one—having had firsthand experience with HZO, she was driven to seek out preventive solutions for others affected by this condition. 

Her dedication brought together resources and expertise to launch this expansive study, highlighting the potential for valacyclovir as a vital therapeutic option and offering renewed hope for patients seeking long-term management of HZO complications.

Research Findings

In the sections that follow, we’ll profoundly discuss the fundamental findings of the Zoster Eye Disease Study (ZEDS) and what they reveal about managing herpes zoster ophthalmicus (HZO). You’ll learn about the study’s impact on reducing HZO complications, the role of long-term antiviral treatment, and how these insights could shape future care approaches for shingles-related eye disease.

Reduction in Eye Disease and Inflammation

One of the most impactful outcomes from the ZEDS study was the observed 26% decrease in eye disease development or worsening among participants treated with valacyclovir. This finding highlights the potential of low-dose antiviral therapy to prevent serious complications like keratitis and iritis, both of which are linked to chronic inflammation and vision impairment. By lowering the risk of these conditions, the study suggests that antiviral treatment could play a significant role in protecting long-term eye health in patients at risk for HZO.

Decrease in Recurrence of Eye Flare-Ups

A marked reduction in eye disease flare-ups was also noted, with participants on valacyclovir experiencing fewer flare-ups at both the 12- and 18-month marks. Specifically, a 30% reduction was recorded at 12 months and 28% at 18 months, underscoring the potential of long-term antiviral use to stabilize eye health over time. These results indicate that valacyclovir may be effective in not only reducing flare-up frequency but also in maintaining more consistent eye health for patients facing recurrent HZO.

Reduced Dependency on Pain Medications

The study also revealed that participants receiving valacyclovir reported shorter durations of pain and reduced reliance on neuropathic pain medications. This reduction is particularly beneficial for older adults, who are often more susceptible to the side effects of these drugs. These side effects may include drowsiness, dizziness, and cognitive changes. With less dependency on such medications, patients may experience improved comfort and fewer complications, making long-term antiviral therapy a valuable strategy for both pain relief and safety.

Benefits of Long-Term, Low-Dose Antiviral Treatment

Here’s a closer look at how continuous antiviral therapy could play an important role in improving patient outcomes and quality of life.

1. Improved Eye Health and Vision Preservation

Continuous use of low-dose antivirals, as observed in the ZEDS study, appears to offer lasting protection against severe eye inflammation and scarring, which can lead to progressive vision loss. By acting as a preventative measure, this treatment helps maintain eye health and preserves vision, potentially sparing patients from the damaging effects of recurring inflammation. This finding highlights the value of antiviral therapy in safeguarding vision for those at risk of shingles-related eye complications.

2. Enhanced Quality of Life

For many patients, particularly older adults, reduced dependence on neuropathic pain medications means fewer side effects that can impair daily activities and quality of life. With valacyclovir effectively managing pain, patients experience a decreased need for additional medication, avoiding common side effects like fatigue and cognitive disruptions. This improvement enhances daily functioning and also supports a more fulfilling, less medicated lifestyle for those managing HZO symptoms.

3. Cost-Effectiveness and Accessibility

Valacyclovir’s affordability and established safety profile make it a practical choice for long-term treatment, providing an accessible option for managing chronic shingles-related conditions in at-risk patients. 

As a widely available and relatively inexpensive antiviral, valacyclovir may ease financial pressures for both patients and healthcare providers, while delivering consistent and reliable results in eye disease prevention. This cost-effective solution aligns well with the needs of patients seeking sustainable, long-term care for HZO.

Implications for Clinical Practice

The following sections deal with how the findings from the Zoster Eye Disease Study (ZEDS) could influence future clinical practices in managing herpes zoster ophthalmicus (HZO). By examining potential adjustments in treatment protocols and personalized approaches, these insights provide a framework for enhancing patient care and long-term management options for shingles-related eye disease.

Potential Shift in Treatment Protocols

The ZEDS findings suggest a potential shift in HZO management, encouraging clinicians to consider long-term, low-dose antiviral regimens as part of standard care. Integrating this preventative approach could reduce the incidence of severe eye complications, allowing practitioners to proactively manage HZO risks alongside other shingles treatments. This shift could be especially beneficial for patients who are prone to recurrent eye disease due to shingles.

Personalized Treatment Approaches

The study also points to a future of more personalized treatment plans, where clinicians customize long-term antiviral use based on each patient’s specific health background, current eye health, and pain management requirements. Such personalized approaches have the potential to optimize outcomes, providing effective care without over-reliance on medication, and may become a standard practice for treating HZO and similar conditions.

The Role of Vaccination

Although the ZEDS study supports the benefits of long-term antiviral therapy, vaccination remains the primary method for shingles prevention. The Shingrix vaccine, which is recommended for adults over 50, has shown high effectiveness in preventing shingles and its complications. Together, vaccination and long-term antiviral treatment provide an extensive strategy for managing HZO, focusing on both prevention and effective management of any arising complications, for holistic patient care.

Our Take at Lens.com 

The Zoster Eye Disease Study provides new insights into managing shingles-related eye disease, showing that long-term, low-dose antiviral treatment can significantly reduce the risk of eye disease, lessen the frequency of flare-ups, and lower reliance on pain medications. These findings underscore the potential for improved quality of life for patients who struggle with HZO and other shingles complications.

While ZEDS has established the effectiveness of long-term antiviral therapy, additional research could explore optimal dosing and the broader benefits of this approach. Expanding studies to include diverse demographics, particularly younger patients or those with compromised immune systems, could reveal further applications for long-term antiviral care.

Greater awareness of shingles and its potential complications is vital, especially as the population ages. Vaccination remains the first line of defense, and for those at risk of HZO, long-term antiviral management offers a promising solution. Encouraging individuals to seek both preventive measures and timely treatment can help mitigate the health burden of shingles, empowering patients to protect their eye health and overall quality of life.